Research-only educational guide

Selank Dosage Calculator and Chart

A structured summary of published literature discussing Selank (a tuftsin analog), including reported dosing concepts, pharmacology discussion, experimental applications, and safety considerations described in research contexts.

Selank Dosage Chart: Quick Breakdown

The table below summarizes the charted dosing structure described in the provided guide as an informational reference only (not a clinical guideline).

Example dosing structure for nootropic research contexts (informational reference only).
Timeframe Injectable Selank (daily total) Intranasal Selank (daily total)
Weeks 1–2 150–300 mcg/day [20] 600–900 mcg/day [19]
Week 3 Washout [19,21] Washout [19,21]
Week 4 150–300 mcg/day [20] 600–900 mcg/day [19]

The guide notes that effects may vary by route of administration and subject factors that influence absorption, distribution, metabolism, and elimination. [3,4]

What Is Selank?

Selank was developed in the early 1990s by researchers at the Russian Academy of Medical Sciences and has been investigated for anxiolytic and cognitive effects. [1]

It is described as a synthetic version of tuftsin, with an added three–amino-acid fragment to improve stability, and has been discussed as modulating GABAergic signaling (including GABAA receptor–related mechanisms) in the literature. [1,2]

Pharmacology / context notes

  • Effects may differ by route (e.g., intranasal vs. systemic administration) in experimental models. [3,4]
  • The guide notes it is not approved by the FDA for therapeutic use. [5]

Selank vs. N-Acetyl Selank Amidate

N-Acetyl Selank Amidate (also referred to as Selank-Amidate / MESELANK in the guide) is described as a modified version of Selank, involving N-terminal acetylation and amidation intended to increase stability and bioavailability. [6,7]

Key points summarized in the guide

  • Modification aims: stability, bioavailability/absorption, and longer half-life. [6,7]
  • The guide notes limited direct trial data for the modified form and frames its safety profile as uncertain. [6,7]

Benefits of Selank (Research Context)

The items below summarize findings and hypotheses described in the guide and cited literature. These are research findings, not clinical claims.

Anxiety / stress-related findings

  • Guide discusses IL-6 (interleukin-6) and immune-related mechanisms relevant to anxiety/stress phenotypes. [8,9]
  • Clinical-context discussions of generalized anxiety disorder and related treatment optimization appear in cited sources. [11,16,17]

Pain-related (antinociceptive) discussion

  • Guide describes suppression of IL-6 and inhibition of enkephalin-degrading enzymes in the cited literature. [10]
  • Enkephalinase inhibition in human serum is discussed in the cited work. [10]

Cognition / learning and memory

  • Conditioned avoidance / learning optimization in rats is discussed. [12]
  • Experimental work on learning/memory processes is cited. [13]

Benzodiazepine comparison context

  • Guide discusses comparisons versus benzodiazepines in anxiety disorder contexts in cited sources. [11,17]
  • Guide notes discussion of adverse effect differences in referenced materials. [18]

Side Effects of Selank (Safety Notes)

The guide frames Selank as a research compound in many jurisdictions and discusses a low incidence of adverse effects in referenced human/animal research, with many reported issues related to route of administration rather than the peptide itself.

Intranasal administration (reported)

  • Irritation of nasal mucosa / septum and sore throat are listed as possible effects in the guide. [14]
  • Technique considerations for nasal sprays are discussed in cited material. [14]

Subcutaneous administration (reported)

  • Injection-site effects (pain, redness, swelling, etc.) and technique considerations are discussed in cited sources. [15]
  • General injection technique considerations appear in cited nursing/skills material. [21]

The guide also notes discussion about potential long-term receptor desensitization hypotheses with limited long-term data. [21]

Dosage Calculator and Guide (Research Context)

The guide summarizes intranasal package-insert style dosing context (drops of a 0.15% solution for up to 14 days, then a 1–3 week break) and also describes clinical-trial contexts with intranasal dosing up to 21 days and larger total daily amounts. [19,16]

Injectable dosing context (as described)

The guide notes a commonly used injectable range of 100–300 mcg/day described as well-tolerated in referenced material, with variability by individual factors (e.g., body weight/age) discussed in the guide. [20,3]

Cycling / washout discussion

To reduce potential concerns related to GABAergic desensitization, the guide discusses a two-weeks-on / one-to-three-weeks-off style washout approach aligned to intranasal guidance. [19,21]

Sample Selank Dosing Protocol (Nootropic Research)

The table below summarizes the example “how researchers could approach dosing” protocol described in the guide (informational reference only).

Parameter Guide Example
Dose Injectable: 150–300 mcg/day; Intranasal: 600–900 mcg/day (2–3 administrations) [19,20]
Frequency Injectable once daily; intranasal 2–3 times daily depending on total daily dose [19]
Study duration Two weeks on, then at least one week off; repeat a second two-week course if needed [19,21]
Injection technique note Guide discusses subcutaneous administration into adipose tissue areas, rotating sites, and avoiding damaged tissue to reduce scarring and absorption issues. [15]

Reconstitution / Handling (Laboratory Context)

The steps below are presented as a high-level handling overview based on the guide text (not a clinical instruction).

Process overview (as described)

  1. Gather appropriate lab materials. [21]
  2. Calculate quantities needed for target concentration. [21]
  3. Draw only the needed amount of diluent. [22]
  4. Add diluent slowly along the inside wall of the vial at an angle. [22]
  5. Do not shake; allow 10–20 minutes to dissolve, rolling gently if needed. [22]

Handling note

The guide emphasizes avoiding agitation during mixing, using time and gentle handling to support dissolution. [22]

Selank Dosing Guide (Verdict Summary)

The guide describes Selank as a tuftsin analog active in immune and CNS contexts, and summarizes research discussions involving anxiety/stress, pain-related pathways, and cognition/learning outcomes in referenced materials. [8,10,12,13]

Dosing concepts presented here are research-summary statements and should be confined to controlled laboratory or regulated clinical research contexts.

References

  1. Filatova, E., Kasian, A., Kolomin, T., Rybalkina, E., Alieva, A., Andreeva, L., Limborska, S., Myasoedov, N., Pavlova, G., Slominsky, P., & Shadrina, M. (2017). GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Frontiers in Pharmacology, 8, 89. https://doi.org/10.3389/fphar.2017.00089
  2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 11765600, Selank. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
  3. Vasil'eva, E. V., Kondrakhin, E. A., Salimov, R. M., & Kovalev, G. I. (2016). Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksperimental'naia i klinicheskaia farmakologiia, 79(9), 3–11.
  4. Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31. https://doi.org/10.3389/fphar.2016.00031
  5. Tello, C. (2019, November 8). Selank (TP-7) for anxiety + insufficiently investigated uses, dosage, & limitations. SelfDecode Drugs. https://drugs.selfdecode.com/blog/selank-effects/
  6. Ree, R., Varland, S., & Arnesen, T. (2018). Spotlight on protein N-terminal acetylation. Experimental & Molecular Medicine, 50(7), 1–13. https://doi.org/10.1038/s12276-018-0116-z
  7. Amidation – an overview | ScienceDirect Topics. (n.d.). https://www.sciencedirect.com/topics/engineering/amidation
  8. Ting, E. Y., Yang, A. C., & Tsai, S. J. (2020). Role of Interleukin-6 in depressive disorder. International Journal of Molecular Sciences, 21(6), 2194. https://doi.org/10.3390/ijms21062194
  9. Uchakina, O. N., Uchakin, P. N., Miasoedov, N. F., Andreeva, L. A., Shcherbenko, V. E., Mezentseva, M. V., Gabaeva, M. V., Sokolov, O. Iu, Zozulia, A. A., & Ershov, F. I. (2008). Immunomodulatry effects of selank in patients with anxiety-asthenic disorders. S.S. Korsakova, 108(5), 71–75.
  10. Kost, N. V., Sokolov, O. Iu, Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
  11. Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Iu, et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. S.S. Korsakova, 108(4), 38–48.
  12. Kozlovskii, I. I., & Danchev, N. D. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology, 33(7), 639–643. https://doi.org/10.1023/a:1024444321191
  13. Semenova, T. P., Kozlovskiĭ, I. I., Zakharova, N. M., & Kozlovskaia, M. M. (2010). Experimental optimization of learning and memory processes by selank. Eksp Klin Farmakol, 73(8), 2–5.
  14. How to Use Nasal Sprays Correctly. (2016, November 15). News-Medical.net. https://www.news-medical.net/health/How-to-Use-Nasal-Sprays-Correctly.aspx
  15. Kim, H., Park, H., & Lee, S. J. (2017). Effective method for drug injection into subcutaneous tissue. Scientific Reports, 7(1), 9613. https://doi.org/10.1038/s41598-017-10110-w
  16. Medvedev, V. E., Tereshchenko, O. N., Kost, N. V., Ter-Israelyan, A. Y., Gushanskaya, E. V., Chobanu, I. K., Sokolov, O. Y., & Myasoedov, N. F. (2015). Optimization of the treatment of anxiety disorders with selank. S.S. Korsakova, 115(6), 33–40. https://doi.org/10.17116/jnevro20151156133-40
  17. Medvedev, V. E., Tereshchenko, O. N., Israelian, A. Iu, Chobanu, I. K., Kost, N. V., Sokolov, O. Iu, & Miasoedov, N. F. (2014). A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. S.S. Korsakova, 114(7), 17–22.
  18. Kasian, A., Kolomin, T., Andreeva, L., Bondarenko, E., Myasoedov, N., Slominsky, P., & Shadrina, M. (2017). Peptide selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology, 2017, 5091027. https://doi.org/10.1155/2017/5091027
  19. Seeds, W. (2020). Peptide Protocols (1st ed.). Seeds Scientific Performance Research. Retrieved from https://www.perlego.com/book/2898727/peptide-protocols-volume-one-pdf
  20. Doyno, C. R., & White, C. M. (2021). Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. The Journal of Clinical Pharmacology, 61(S2). https://doi.org/10.1002/jcph.1922
  21. Ernstmeyer, & Christman (Eds.). (2022, March 24). 18.2: Basic Concepts: Syringes. Medicine LibreTexts. https://med.libretexts.org/Bookshelves/Nursing/Nursing_Skills_(OpenRN)/18%3A_Administration_of_Parenteral_Medications/18.02%3A_Basic_Concepts

Educational content for research discussion only. Not medical advice.